A G Pallis

Summary

Publications

  1. ncbi Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
    A G Pallis
    EORTC Elderly Task Force Member and Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Cancer Treat Rev 36:436-41. 2010
  2. ncbi EORTC elderly task force position paper: approach to the older cancer patient
    A G Pallis
    European Organization for Research and Treatment of Cancer, Elderly Task Force, EORTC Headquarters, Avenue E Mounierlaan, 83 11, B 1200 Brussels, Belgium
    Eur J Cancer 46:1502-13. 2010
  3. ncbi Lung cancer in never smokers: disease characteristics and risk factors
    Athanasios G Pallis
    Oncology Unit GPP, Athens School of Medicine, Athens, Greece Electronic address
    Crit Rev Oncol Hematol 88:494-503. 2013
  4. doi Targeting tumor neovasculature in non-small-cell lung cancer
    Athanasios G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Crit Rev Oncol Hematol 86:130-42. 2013
  5. doi Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Lung Cancer 80:120-30. 2013
  6. doi A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group HORG, Athens, Greece
    Clin Lung Cancer 13:129-35. 2012
  7. doi Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care
    Athanasios G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
    Lung Cancer 75:269-74. 2012
  8. pmc A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group, 55 Lombardou str, 114 74 Athens, Greece
    BMC Cancer 10:633. 2010
  9. doi EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 22:1922-6. 2011
  10. pmc Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece
    Br J Cancer 105:1-8. 2011

Detail Information

Publications26

  1. ncbi Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
    A G Pallis
    EORTC Elderly Task Force Member and Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Cancer Treat Rev 36:436-41. 2010
    ..Despite a growing body of data, further work is still needed to establish optimal strategies to care for this special population and prospective specific trials for older NSCLC patients are clearly needed...
  2. ncbi EORTC elderly task force position paper: approach to the older cancer patient
    A G Pallis
    European Organization for Research and Treatment of Cancer, Elderly Task Force, EORTC Headquarters, Avenue E Mounierlaan, 83 11, B 1200 Brussels, Belgium
    Eur J Cancer 46:1502-13. 2010
    ..The purpose of this paper is to focus on the influence of age on cancer presentation and cancer management in older cancer patients and to provide suggestions on clinical trial development and methodology in this population...
  3. ncbi Lung cancer in never smokers: disease characteristics and risk factors
    Athanasios G Pallis
    Oncology Unit GPP, Athens School of Medicine, Athens, Greece Electronic address
    Crit Rev Oncol Hematol 88:494-503. 2013
    ..The purpose of this review is to summarize our current knowledge of this disease...
  4. doi Targeting tumor neovasculature in non-small-cell lung cancer
    Athanasios G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Crit Rev Oncol Hematol 86:130-42. 2013
    ..The purpose of this paper is to present the current status of antiangiogenic therapies in the treatment of NSCLC and to discuss these issues...
  5. doi Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Lung Cancer 80:120-30. 2013
    ..The purpose of this paper is to present the relevant clinical data, describe the predictive markers available for TKIs treatment in NSCLC, and describe the mechanisms associated with resistance to treatment with these agents...
  6. doi A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group HORG, Athens, Greece
    Clin Lung Cancer 13:129-35. 2012
    ..The purpose of this study was to evaluate the efficacy of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer (NSCLC)...
  7. doi Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care
    Athanasios G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
    Lung Cancer 75:269-74. 2012
    ....
  8. pmc A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group, 55 Lombardou str, 114 74 Athens, Greece
    BMC Cancer 10:633. 2010
    ..To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  9. doi EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Ann Oncol 22:1922-6. 2011
    ..A multidisciplinary approach to the senior adult cancer patient is mandatory, to assure optimal diagnosis and therapeutic management...
  10. pmc Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece
    Br J Cancer 105:1-8. 2011
    ..Use of other biomarkers remains investigational...
  11. doi Are we treating enough elderly patients with early stage non-small cell lung cancer?
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Voutes Stavrakion Embranchement, 71305 Heraklion, Greece
    Lung Cancer 74:149-54. 2011
    ..Given the lack of demonstrated benefit for the use of adjuvant RT it is also not recommended in older population...
  12. doi Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group
    A G Pallis
    Hellenic Oncology Research Group, Athens, Greece
    Ann Oncol 22:2448-55. 2011
    ..Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%-40% of cases occur in patients >70 years...
  13. ncbi Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 62:356-63. 2008
    ..One of its more common side effects is neutropenia. The association between the grade of DG-induced neutropenia and the clinical outcome was analyzed...
  14. doi Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis
    N Maniadakis
    Department of Health Services Management, National School of Public Health, Athens, Greece
    Ann Oncol 21:1462-7. 2010
    ....
  15. ncbi Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 55:101-7. 2007
    ..To evaluate the activity and toxicity of the sequential administration of docetaxel followed by gefitinib in patients with advanced non-small cell lung cancer (NSCLC)...
  16. doi A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
    A G Pallis
    Breast Cancer Study Group, Hellenic Oncology Research Group HORG, Athens, Greece
    Ann Oncol 23:1164-9. 2012
    ..The primary objective was to demonstrate superiority of combination treatment in terms of progression-free survival (PFS)...
  17. doi EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population
    A G Pallis
    EORTC Headquarters, EORTC ETF, Avenue E Mounierlaan 83 11, Brussels, Belgium
    Ann Oncol 21:692-706. 2010
    ..Prospective elderly-specific trials are needed...
  18. pmc 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Br J Cancer 97:1560-6. 2007
    ..The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study...
  19. doi Questionnaires and instruments for a multidimensional assessment of the older cancer patient: what clinicians need to know?
    A G Pallis
    European Organization for Research and Treatment of Cancer, Elderly Task Force, EORTC Headquarters, Avenue E Mounierlaan, 83 11, B 1200 Brussels, Belgium
    Eur J Cancer 46:1019-25. 2010
    ..In the present paper, we discuss the most commonly used and studied tools for the assessment of functional status of older cancer patients...
  20. doi Targeted therapies in the treatment of advanced/metastatic NSCLC
    A G Pallis
    EORTC Headquarters, EORTC ETF, Avenue E Mounierlaan, 83 11, Brussels B 1200, Belgium
    Eur J Cancer 45:2473-87. 2009
    ..The purpose of this study is to review current data on the role of targeted therapies in the treatment of advanced NSCLC...
  21. doi EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients
    A G Pallis
    EORTC Headquarters, EORTC Elderly Task Force, Brussels, Belgium
    Cancer Treat Rev 36:83-90. 2010
    ..Despite a growing body of data, further work is still needed to establish optimal strategies to care for this special population and prospective specific trials for older colon cancer patients are clearly needed...
  22. ncbi Quality of life of Greek patients with inflammatory bowel disease. Validation of the Greek translation of the inflammatory bowel disease questionnaire
    A G Pallis
    Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Greece
    Digestion 63:240-6. 2001
    ..CONCLUSIONS: The Greek IBDQ proved to be a valid and reliable instrument for assessing HRQOL, useful in the evaluation of clinical trials or health surveys as well as in the therapeutic management of IBD patients...
  23. ncbi ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program
    A G Pallis
    Department of Medical Oncology, University Hospital of Heraklion, P O Box 1352, 71110 Heraklion, Crete, Greece
    Lung Cancer 40:301-7. 2003
    ....
  24. pmc Small cell ovarian cancer in adolescents: report of two cases and review of the literature
    M Rovithi
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 711 10 Heraklion, Crete, Greece
    Case Report Med 2011:749516. 2011
    ..Herein, we report two cases of small cell carcinoma of the ovaries along with a review of the relevant literature...
  25. ncbi The inflammatory bowel disease questionnaire: a review of its national validation studies
    A G Pallis
    Department of Gastroenterology, University Hospital of Heraklion, Heraklion, Crete, Greece
    Inflamm Bowel Dis 10:261-9. 2004
    ..Assessing HRQoL in patients with IBD is an ever-increasing practice, especially in clinical trials. IBDQ was proven to be valid and reliable in several cultural and linguistic milieus when appropriate validation procedures were applied...
  26. ncbi Adjuvant chemotherapy for colon cancer
    A G Pallis
    Gastroenterology Department, University Hospital of Heraklion, Heraklion, Greece
    Anticancer Res 26:4809-15. 2006
    ....